# US Blood Screening Market

> United States Blood Screening Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.23%
- **2024:** $ 816 Million
- **2025:** $ 899.28 Million
- **2035:** $ 2,155.2 Million
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (US), Thermo Fisher Scientific (US), Siemens Healthineers (US), Grifols (US), Hologic (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Becton Dickinson and Company (US)

**Report ID:** MRFR/MED/13969-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-blood-screening-market-15496

---

## Market Summary

## US Blood Screening Market Highlighted Trends & Dynamics

The demand for blood screening in the United States has witnessed a significant upsurge, driven by the imperative need for ensuring the safety and reliability of blood transfusions. This burgeoning demand can be attributed to a variety of factors, ranging from the increasing prevalence of infectious diseases to the growing number of complex medical procedures requiring blood products. Blood screening plays a pivotal role in safeguarding the integrity of the nation's blood supply, as it helps identify and eliminate potential contaminants such as viruses, bacteria, and other pathogens.

The continuous evolution of screening technologies has further fueled the demand, as more advanced methods offer enhanced accuracy and efficiency.

One of the primary drivers of the US blood screening market is the rising awareness and emphasis on public health. With an increasing awareness of the risks associated with bloodborne diseases, both among healthcare professionals and the general public, there is a growing push for comprehensive blood screening protocols. This heightened awareness has been particularly evident in the wake of global health crises, which has underscored the importance of maintaining a robust and secure blood supply chain. Consequently, healthcare institutions, blood banks, and regulatory bodies are investing in advanced blood screening technologies to meet these evolving challenges.

Technological advancements in blood screening methods have also played a pivotal role in shaping the demand landscape. Traditional screening methods have been augmented or replaced by nucleic acid testing (NAT), polymerase chain reaction (PCR), and other molecular techniques, offering higher sensitivity and specificity in detecting infections. The advent of automation and robotics in blood screening processes has not only increased efficiency but has also reduced human errors, thereby contributing to the overall reliability of screening results. These technological innovations have garnered substantial interest and investment, further boosting the demand for cutting-edge blood screening solutions.

Moreover, the increasing prevalence of chronic diseases, coupled with a growing aging population, has led to a surge in the demand for blood and blood components. Conditions such as cancer, hemophilia, and autoimmune disorders necessitate frequent blood transfusions, intensifying the need for a rigorous and efficient blood screening infrastructure. This has prompted healthcare providers to prioritize the implementation of advanced blood screening technologies to ensure the safety of blood products and minimize the risk of transfusion-related complications.

The regulatory landscape also plays a pivotal role in driving the demand for blood screening services. Strict regulatory requirements and standards set by organizations such as the Food and Drug Administration (FDA) necessitate comprehensive screening protocols to ensure the safety of blood products. Compliance with these regulations is paramount for blood banks and healthcare facilities, compelling them to invest in state-of-the-art screening technologies and infrastructure to meet stringent quality control measures.

## Market Drivers

### Growth of the Blood Donation Sector

The growth of the blood donation sector is a pivotal factor influencing the US [Blood Screening](https://www.marketresearchfuture.com/reports/blood-screening-market-6899) Market. As the demand for blood products continues to rise, blood banks and donation centers are increasingly focusing on implementing rigorous screening processes to ensure the safety of the blood supply. The American Red Cross reports that approximately 13.6 million units of whole blood are collected annually in the US, necessitating efficient and reliable blood screening methods. This surge in blood donations is likely to drive investments in advanced screening technologies, as organizations seek to enhance their testing capabilities. Additionally, collaborations between blood donation organizations and healthcare providers are fostering the development of innovative screening solutions. Consequently, the market is poised for growth as the blood donation sector expands and prioritizes the safety and quality of blood products.

### Regulatory Enhancements and Compliance

Regulatory enhancements play a crucial role in shaping the US Blood Screening Market. The Food and Drug Administration (FDA) has implemented stringent guidelines to ensure the safety and efficacy of blood screening tests. Compliance with these regulations is essential for manufacturers and laboratories, as it not only ensures patient safety but also enhances market credibility. The FDA's focus on post-market surveillance and real-time monitoring of blood screening products has led to increased investments in quality assurance processes. This regulatory landscape is expected to drive innovation, as companies strive to meet compliance standards while developing new products. The emphasis on regulatory compliance is likely to foster a competitive environment, encouraging firms to enhance their offerings and expand their market share.

### Rising Incidence of Bloodborne Diseases

The rising incidence of bloodborne diseases in the United States is a significant driver for the US Blood Screening Market. Conditions such as hepatitis B, hepatitis C, and HIV continue to pose serious public health challenges. According to the CDC, approximately 3.9 million people in the US are living with chronic hepatitis C, underscoring the urgent need for effective blood screening solutions. This alarming trend is prompting healthcare providers to enhance their screening protocols, thereby increasing the demand for advanced blood screening technologies. Furthermore, the growing prevalence of these diseases is likely to lead to increased funding for research and development in the blood screening sector. As healthcare systems strive to mitigate the impact of these diseases, the market is expected to expand in response to the pressing need for comprehensive blood screening services.

### Technological Advancements in Blood Screening

The US Blood Screening Market is experiencing a notable transformation due to rapid technological advancements. Innovations such as nucleic acid testing (NAT) and next-generation sequencing (NGS) are enhancing the accuracy and speed of blood screening processes. These technologies allow for the detection of pathogens at lower levels, thereby improving safety standards. The market is projected to grow at a compound annual growth rate (CAGR) of approximately 7.5% from 2025 to 2030, driven by the increasing adoption of these advanced methodologies. Furthermore, automation in laboratories is streamlining workflows, reducing human error, and increasing throughput. As a result, healthcare providers are more inclined to invest in state-of-the-art blood screening technologies, which is likely to bolster the overall market growth.

### Increased Public Awareness and Health Initiatives

In recent years, there has been a marked increase in public awareness regarding bloodborne diseases and the importance of blood screening. The US Blood Screening Market benefits from various health initiatives aimed at educating the public about the risks associated with transfusion-transmissible infections. Campaigns led by organizations such as the Centers for Disease Control and Prevention (CDC) have highlighted the significance of regular blood screening, particularly for high-risk populations. This heightened awareness is likely to drive demand for blood screening services, as individuals become more proactive about their health. Additionally, partnerships between public health agencies and private sector entities are fostering community outreach programs, further promoting the necessity of blood screening. As a result, the market is expected to witness sustained growth fueled by an informed and health-conscious populace.

## Future Outlook

The US Blood Screening Market is projected to grow at a 9.23% CAGR from 2025 to 2035, driven by technological advancements, increasing disease prevalence, and regulatory support.

**New opportunities:**

- Development of AI-driven diagnostic tools for enhanced accuracy Expansion of mobile blood screening units for remote access Partnerships with healthcare providers for integrated screening solutions

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Infectious Disease Testing (Largest) vs. Transfusion (Fastest-Growing)

In the US Blood Screening Market, the application segment is primarily driven by the demand for Infectious Disease Testing, which dominates the market share. It plays a crucial role in ensuring the safety of blood products by detecting various pathogens. Following this, Transfusion services are gaining traction due to the rising necessity for blood transfusions in medical procedures, indicating a significant opportunity for growth in this area. Other segments, such as Organ Transplantation and Blood Typing, contribute to the overall market but have a smaller share compared to these two leading applications.

Infectious Disease Testing (Dominant) vs. Transfusion (Emerging)

Infectious Disease Testing holds a dominant position in the US Blood Screening Market due to its critical role in identifying potential infections before blood transfusions. This segment encompasses a range of tests for various pathogens, including HIV, Hepatitis, and West Nile Virus. As public health initiatives and regulatory standards continue to evolve, the emphasis on safe blood supply has intensified, consolidating the prominence of infectious disease testing. On the other hand, Transfusion is an emerging application fueled by increased surgical procedures and an aging population, driving demand for blood products. This segment is expected to see substantial growth as healthcare providers focus on ensuring adequate blood supply and improving transfusion protocols.

### By End Use: Hospitals (Largest) vs. Blood Banks (Fastest-Growing)

In the US Blood Screening Market, the 'End Use' segment reveals a diverse distribution among key players, with hospitals leading the market as the largest segment. This dominance is fueled by their robust infrastructure and integrated healthcare services, allowing for extensive blood screening processes. In contrast, blood banks, while smaller in market share compared to hospitals, are emerging as the fastest-growing segment, primarily due to increasing awareness about blood donation and innovative technologies enhancing the screening process. 

Diagnostic laboratories and research institutions also play vital roles, catering to specific needs in diagnostics and scientific exploration, respectively. However, their contributions to market share are less pronounced compared to hospitals and blood banks. The growth in demand for accurate and efficient blood screening methods further solidifies the presence of these segments, showcasing a dynamic landscape in the US Blood Screening Market.

Hospitals (Dominant) vs. Blood Banks (Emerging)

Hospitals stand as the dominant force in the US Blood Screening Market due to their comprehensive healthcare services and immediate access to patient populations requiring constant blood testing and screening. With established protocols and high standards for safety, hospitals ensure quality care and timely diagnostic services. Meanwhile, blood banks represent an emerging segment, experiencing rapid growth driven by innovative technologies and increasing public engagement in voluntary blood donations. They are adapting to meet the rising demands for screened blood products, facilitated by advancements in automation and data management systems. This evolution positions blood banks as crucial players in easing the pressures on hospitals while ensuring a safe and adequate blood supply for medical emergencies.

### By Technology: Nucleic Acid Testing (Largest) vs. Enzyme-Linked Immunosorbent Assay (Fastest-Growing)

In the US Blood Screening Market, the technology segment is marked by distinct differences in market share among its key components: Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Immunoassay, and [Polymerase Chain Reaction](https://www.marketresearchfuture.com/reports/polymerase-chain-reaction-market-19212) (PCR). Nucleic Acid Testing holds the largest portion of the market due to its ability to detect pathogens at a much earlier stage compared to other methods. ELISA, though smaller in market share, is rapidly gaining traction, especially in the context of emerging infectious diseases, thus creating a competitive landscape among these technologies.

Technology: Nucleic Acid Testing (Dominant) vs. Enzyme-Linked Immunosorbent Assay (Emerging)

Nucleic Acid Testing, often regarded as the dominant technology in the US Blood Screening Market, is renowned for its high sensitivity and speed in identifying infectious agents like HIV and Hepatitis. Its widespread adoption is fueled by increasing regulatory requirements and a growing emphasis on early disease detection. On the other hand, Enzyme-Linked Immunosorbent Assay is emerging due to its cost-effectiveness and versatility in screening various blood-borne pathogens. ELISA’s rapid development in response to new health threats further enhances its position as a promising technology. Together, these methodologies illustrate a dynamic interplay in a market marked by innovation and the need for reliable diagnostic solutions.

## Competitive Benchmarking

The Blood Screening Market in the US is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and technological advancements. Key players such as Abbott Laboratories (US), Roche Diagnostics (US), and Thermo Fisher Scientific (US) are at the forefront, leveraging their extensive research capabilities and product portfolios to enhance their market positions. Abbott Laboratories (US) focuses on developing cutting-edge diagnostic solutions, while Roche Diagnostics (US) emphasizes personalized healthcare through advanced blood screening technologies. Thermo Fisher Scientific (US) appears to be concentrating on expanding its global footprint, particularly in emerging markets, thereby intensifying competition within the sector.
The market structure is moderately fragmented, with several players vying for market share through various business tactics. Companies are increasingly localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing and ensuring timely delivery of products. This localized approach, combined with strategic collaborations, enhances operational efficiency and responsiveness to market demands, thereby shaping the competitive dynamics of the Blood Screening Market.
In December 2025, Abbott Laboratories (US) announced the launch of a new rapid blood screening test designed to detect multiple infectious diseases simultaneously. This innovation is expected to significantly enhance diagnostic accuracy and speed, positioning Abbott as a leader in the market. The strategic importance of this launch lies in its potential to address the growing demand for efficient and comprehensive blood screening solutions, thereby reinforcing Abbott's competitive edge.
In November 2025, Roche Diagnostics (US) entered into a partnership with a leading biotechnology firm to develop next-generation blood screening technologies utilizing artificial intelligence (AI). This collaboration aims to enhance the accuracy and efficiency of blood tests, reflecting Roche's commitment to integrating advanced technologies into its product offerings. The strategic significance of this partnership is profound, as it not only strengthens Roche's innovation pipeline but also positions the company to capitalize on the increasing trend towards AI-driven healthcare solutions.
In October 2025, Thermo Fisher Scientific (US) acquired a smaller diagnostics company specializing in blood screening technologies. This acquisition is indicative of Thermo Fisher's strategy to bolster its product portfolio and expand its capabilities in the blood screening domain. The strategic importance of this move lies in the potential for enhanced research and development capabilities, which could lead to the introduction of novel blood screening solutions that meet evolving market needs.
As of January 2026, the Blood Screening Market is witnessing trends such as digitalization, sustainability, and the integration of AI technologies. These trends are reshaping competitive strategies, with companies increasingly forming strategic alliances to enhance their technological capabilities and market reach. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, suggesting a transformative shift in how companies position themselves in the market.

## Report Scope

| MARKET SIZE 2024 | 816.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 899.28(USD Million) |
| MARKET SIZE 2035 | 2155.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.23% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (US), Thermo Fisher Scientific (US), Siemens Healthineers (US), Grifols (US), Hologic (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Becton Dickinson and Company (US) |
| Segments Covered | Application, End Use, Technology |
| Key Market Opportunities | Integration of advanced technologies enhances efficiency and accuracy in the US Blood Screening Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the US Blood Screening Market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US Blood Screening Market?**
A: As of 2024, the US Blood Screening Market was valued at 816.0 USD Million.

**Q: What is the projected market valuation for the US Blood Screening Market in 2035?**
A: The market is projected to reach a valuation of 2155.2 USD Million by 2035.

**Q: What is the expected CAGR for the US Blood Screening Market during the forecast period?**
A: The expected CAGR for the US Blood Screening Market from 2025 to 2035 is 9.23%.

**Q: Which applications dominate the US Blood Screening Market?**
A: In 2024, Infectious Disease Testing led the market with a valuation range of 300.0 to 800.0 USD Million.

**Q: How do hospitals and blood banks compare in terms of market share?**
A: In 2024, blood banks had a valuation range of 250.0 to 700.0 USD Million, while hospitals ranged from 200.0 to 550.0 USD Million.

**Q: What technologies are primarily used in blood screening?**
A: Nucleic Acid Testing and Enzyme-Linked Immunosorbent Assay are key technologies, with valuations of 200.0 to 600.0 USD Million and 250.0 to 700.0 USD Million, respectively.

**Q: Who are the leading companies in the US Blood Screening Market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, among others.

**Q: What is the market performance of therapeutic drug monitoring in blood screening?**
A: Therapeutic Drug Monitoring had a valuation range of 166.0 to 405.2 USD Million in 2024.

**Q: What role do diagnostic laboratories play in the US Blood Screening Market?**
A: Diagnostic laboratories contributed a valuation range of 250.0 to 600.0 USD Million in 2024.

**Q: What is the significance of organ transplantation in the blood screening sector?**
A: Organ transplantation accounted for a valuation range of 100.0 to 300.0 USD Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-blood-screening-market-15496*